These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19896588)

  • 21. Diagnosis of dementia and treatment of Alzheimer's disease. Pharmacologic management of disease progression and cognitive impairment.
    van Reekum R; Simard M; Farcnik K
    Can Fam Physician; 1999 Apr; 45():945-52. PubMed ID: 10216793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing health economic outcome in Alzheimer's disease clinical trials.
    Jonsson L
    J Nutr Health Aging; 2007; 11(4):353-5. PubMed ID: 17653498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
    Emre M
    Int J Clin Pract Suppl; 2002 Jun; (127):64-72. PubMed ID: 12139369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenomics in Alzheimer's disease.
    Cacabelos R
    Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
    Harry RD; Zakzanis KK
    Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.
    Cappell J; Herrmann N; Cornish S; Lanctôt KL
    CNS Drugs; 2010 Nov; 24(11):909-27. PubMed ID: 20932064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel subject synchronization clinical trial design for Alzheimer's disease.
    Schultz T; Yang E; Farnum M; Lobanov V; Verbeeck R; Raghavan N; Samtani MN; Novak G; Shi Y; Narayan V; DiBernardo A
    J Alzheimers Dis; 2012; 31(3):507-16. PubMed ID: 22614878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of genetic testing for risk of Alzheimer's disease.
    Kane RA; Kane RL
    N Engl J Med; 2009 Jul; 361(3):298-9. PubMed ID: 19605835
    [No Abstract]   [Full Text] [Related]  

  • 31. Alzheimer's disease: aging, insomnia and epigenetics.
    Wu TY; Chen CP; Jinn TR
    Taiwan J Obstet Gynecol; 2010 Dec; 49(4):468-72. PubMed ID: 21199749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug delivery strategies for Alzheimer's disease treatment.
    Di Stefano A; Iannitelli A; Laserra S; Sozio P
    Expert Opin Drug Deliv; 2011 May; 8(5):581-603. PubMed ID: 21391862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disclosure of the genetic risk of Alzheimer's disease.
    Gordon SC; Landa D
    N Engl J Med; 2010 Jan; 362(2):181-2; author reply 182. PubMed ID: 20071713
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques.
    Modrego PJ
    Curr Med Chem; 2006; 13(28):3417-24. PubMed ID: 17168714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prescribing drugs for Alzheimer's disease in primary care: managing cognitive symptoms.
    Drug Ther Bull; 2014 Jun; 52(6):69-72. PubMed ID: 24924683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers for the early stages of clinical development in Alzheimer's disease.
    Bordet R; Dartigues JF; Dubois B; Goehrs JM; Vernoux L; Semah F; Pasquier F; Bidaut-Mazel C;
    Therapie; 2010; 65(4):285-90, 277-283. PubMed ID: 20854749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of Discrete-Event Simulation in Health Technology Assessment: A Cost-Effectiveness Analysis of Alzheimer's Disease Treatment Using Real-World Evidence in Thailand.
    Kongpakwattana K; Chaiyakunapruk N
    Value Health; 2020 Jun; 23(6):710-718. PubMed ID: 32540228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology of Alzheimer's disease: appraisal and prospects.
    Sellal F; Nieoullon A; Michel G; Michel BF; Lacomblez L; Geerts H; Delini Stula A; Bordet R; Bentué-Ferrer D; Allain H
    Dement Geriatr Cogn Disord; 2005; 19(5-6):229-45. PubMed ID: 15767760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current treatment options for people with Alzheimer's disease in Croatia.
    Mimica N; Presecki P
    Chem Biol Interact; 2010 Sep; 187(1-3):409-10. PubMed ID: 20307517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2014; 42(1):1-68. PubMed ID: 24903780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.